Clinical trial NCT03273322: Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure
Official title: Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure: The Randomized ADRIFT Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Atrial Fibrillation
Atrial Appendage
Hemorrhage
Keywords: Left atrial appendage closure
Rivaroxaban
Dual antiplatelet therapy
Anticoagulation
Stroke prevention
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
Collaborators: name: Action Research Group
name: Bayer
First posted: 2017-09-06
Enrollment: 105
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluation of 2 doses of rivaroxaban (10 and 15 mg) compared to dual anti platelet therapy (aspirin+clopidogrel) after left atrial appendage closure. The patients will be assessed at 10 and 90 days: central laboratory hemostasis analysis and clinical events assessment.

Detailed description: Data on antithrombotic therapy after Left Atrial Appendage Closure (LAAC) are scarce and no randomized evaluation has been performed to demonstrate what is the best antithrombotic strategy following LAAC. LAAC is classically associated with a 6-week period of anticoagulation with warfarin + aspirin followed by once daily clopidogrel (75 mg) + aspirin (81-325 mg) until the 6 months visit, then aspirin alone is continued indefinitely, as tested in patients without contraindication for anticoagulation in the pivotal Watchman trials. LAAC is mostly used in Europe as an alternative to warfarin anticoagulation when patients have a contraindication to or are unsuitable for warfarin anticoagulation. The classic regimen is not applicable and believed to be too risky in such frail patients. These patients usually receive a regimen of daily clopidogrel + aspirin followed by single antiplatelet therapy (most frequently used treatment). Some patients receive oral anticoagulation without aspirin, including NOAC anticoagulation. Rivaroxaban is a tempting strategy for anticoagulation following LAAC in atrial fibrillation (AF) patients. The dose needs first to be carefully evaluated the trial propose a dose ranging study in patients who have undergone successful LAAC.

The study will evaluate two different Rivaroxaban regimen (10 or 15 mg a day) in comparison to dual antiplatelet therapy (DAPT) (aspirin+clopidogrel : control arm representing standard of care) after successful LAAC. The aim is to investigate whether rivaroxaban could provide correct anticoagulation levels and adequately suppress coagulation activation after LAAC.

The patient will be enrolled after left atrial appendage closure before discharge. The randomization is 1/1/1 between the 3 groups : rivaroxaban 10mg a day, rivaroxaban 15 mg a day and aspirin 75mg + clopidogrel 75 mg a day. At 10 and 90 days, the patients will be sampled for biological assessment : Prothrombin fragments 1+2, Factor Xa inhibitory activity, Russel Viper venom enzyme assay, thrombin anti-thrombin (TAT) complex, D-Dimers, Prothrombin time (Neoplastin) and plasma von Willebrand factor (vWf) Ag level

After 90 days, the patient will end his/her participation in the trial. Clinical endpoints (death, MI, Stroke, TIA, systemic embolism, extracranial major bleeding or clinically relevant non major bleeding) at 90 days will be assessed by a clinical endpoint committee. Central echographic laboratory will review all 90 days transesophageal echocardiography (TEE) to detect the presence of thrombus or peri-device leak.

The study is open-label. Central laboratory, clinical endpoint committee and echographic core laboratory is blinded to randomization arm.

Eligibility criteria: Inclusion Criteria:

* Men and women ≥18 years of age
* Patients who underwent a clinically successful LAAC procedure (device implanted without procedural or bleeding complication). LAAC may have been indicated for patients contraindicated or unsuitable for long-term Vitamin K antagonists (VKA) anticoagulation.
* AF (permanent or persistent or paroxysmal) patients irrespective of prior antithrombotic treatment are eligible for randomization.
* Written informed consent by the patient or designee if the patient is unable to consent
* Patients affiliated to the French social security system

Exclusion Criteria:

* Creatinine clearance \<30 mL / min (Cockcroft formula).
* Dialysis.
* Mechanical heart valves or valvular disease requiring surgery or interventional procedure
* Planned Ablation of AF during follow up period
* Mandatory indication for dual antiplatelet therapy (e.g. recent stent) or single anti-platelet treatment (SAPT) (e.g. high coronary risk).
* Any contra-indication or known allergy to aspirin or clopidogrel or rivaroxaban.
* Any mandatory indication for anticoagulation for a reason other than AF (e.g. Pulmonary embolism)
* Ongoing major bleeding or complicated or recent (\<72hours) major surgery
* Known large oesophageal varices or decompensated liver disease (unless a documented positive opinion of a gastro-enterologist)
* Severe thrombocytopenia (\<50,000/ml) after referral to haematologist to confirm or not contraindication
* Recent myocardial infarction (\<6 weeks).
* Recent cerebro-vascular event (CVE) or transient ischemic attack (\<6 weeks) after evaluation of stroke vs bleeding risk by the referring neurologist.
* Recent Intracranial bleeding (\< 6 months): these patients will be evaluated by a neurologist as these patients may be considered at higher stroke risk. Neurologist may consider that the LAAC procedure with a short (90 days) period of anticoagulation or antiplatelet therapy as tested in the protocol is a preferable option (in that case intracranial hemorrhage (ICH) will not be considered as a contraindication).
* Prasugrel or ticagrelor concomitant use
* Participating in an investigational drug or another device trial within the previous 30 days.
* High likelihood of being unavailable for follow-up or psycho-social condition making study participation impractical.
* Woman with child bearing potential who do not use an efficient method of contraception.
* positive serum or urine pregnancy test for woman with child bearing potential
* Pregnancy or within 48 hours post-partum or breast feeding women
* Patient under legal protection

Primary outcomes:
measure: Measure of prothrombin fragment 1 + 2
timeFrame: at Day 10
Secondary outcomes:
measure: Measure of prothrombin fragment 1 + 2
timeFrame: at Day 90
measure: Factor Xa inhibitory activity at day 10
timeFrame: at Day 10
measure: Factor Xa inhibitory activity at day 90
timeFrame: at Day 90
measure: Russel Viper venom enzyme assay
timeFrame: at Day 90
measure: TAT complex
timeFrame: at Day 10
measure: TAT complex
timeFrame: at Day 90
measure: D-Dimers
timeFrame: at Day 10
measure: D-Dimers
timeFrame: at Day 90
measure: Prothrombin time (Neoplastin)
timeFrame: at Day 10
measure: Prothrombin time (Neoplastin)
timeFrame: at Day 90
measure: Plasma vWf Ag level
timeFrame: at Day 10
measure: Plasma vWf Ag level
timeFrame: at Day 90
measure: Haemorrhagic stroke and bleeding will be safety outcomes TEE with central core lab reading: presence of thrombus, peri-device leak
timeFrame: at Day 90
measure: Composite clinical endpoint combining all clinical outcomes
timeFrame: at Day 90
measure: Death (any cause)
timeFrame: at Day 90
measure: Myocardial infarction (MI)
timeFrame: at Day 90
measure: Stroke (ischaemic stroke, haemorrhagic stroke)
timeFrame: at Day 90
measure: Transient Ischemic Attack (TIA)
timeFrame: at Day 90
measure: Systemic embolism
timeFrame: at Day 90
measure: Extracranial major bleeding or clinically relevant non major bleeding (ISTH definition) at day 90
timeFrame: at Day 90
Other outcomes:
Locations:
city: Paris
country: France
facility: Institut de Cardiologie - Hôpital Pitié-Salpêtrière
Study officials:
affiliation: Centre Hospitalier Universitaire Pitié-Salpêtrière Paris
name: Gilles MONTALESCOT, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Duthoit G, Silvain J, Marijon E, Ducrocq G, Lepillier A, Frere C, Dimby SF, Popovic B, Lellouche N, Martin-Toutain I, Spaulding C, Brochet E, Attias D, Mansourati J, Lorgis L, Klug D, Zannad N, Hauguel-Moreau M, Braik N, Deltour S, Ceccaldi A, Wang H, Hammoudi N, Brugier D, Vicaut E, Juliard JM, Montalescot G. Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study. Circ Cardiovasc Interv. 2020 Jul;13(7):e008481. doi: 10.1161/CIRCINTERVENTIONS.119.008481. Epub 2020 Jul 17.